Clinical trials: Non-Small Cell Lung
Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure.
- Trial name
- NCT01903993
- Testing
- Docetaxel, Atezolizumab
- Where
- 65 sites in United States, Belgium and 11 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
This is an open-label Phase 1b study designed to confirm the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with selected solid tumors (non-small cell lung cancer, predominantly clear cell…
- Trial name
- NCT03006887
- Testing
- lenvatinib, pembrolizumab
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Eisai Co., Ltd.
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Stage IV NSCLC
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
This pilot phase I trial aims to investigate the safety and tolerability of anti-programmed cell death-1 (PD-1) monoclonal antibody Sintilimab (also called IBI308) in combination with concurrent stereotactic body radiation…
- Trial name
- NCT03812549
- Testing
- Sintilimab, stereotactic body radiation therapy, Low Dose Radiotherapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sichuan University
Non Small Cell Lung Cancer
A Study in Non Small Cell Lung Cancer
LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (CHK1). It was being developed as a chemotherapeutic-enhancing agent in the treatment of cancer.
- Trial name
- NCT01139775
- Testing
- Pemetrexed, Cisplatin, LY2603618
- Where
- 24 sites in Germany, Spain
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non Small Cell Lung
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second…
- Trial name
- NCT01671332
- Testing
- Docetaxel, Suramin
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Wisconsin, Madison
Non-Small Cell Lung Cancer
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
This is a Phase 1/2 study of PF-06747775 as a single agent and in combination with other cancer treatments in patients with advanced EGFRm NSCLC.
- Trial name
- NCT02349633
- Testing
- PF-06747775, Palbociclib, Avelumab
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study
In this China extension study, carboplatin and paclitaxel with or without pembrolizumab (MK-3475, KEYTRUDA®) will be administered to Chinese adults with first line metastatic squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT03875092
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with…
- Trial name
- NCT03409614
- Testing
- REGN2810, REGN2810/chemo/ipi, Chemotherapy
- Where
- 133 sites in United States, Austria and 16 more
- Volunteers
- 789 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small Cell Lung Cancer
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.
- Trial name
- NCT02768558
- Testing
- Radiation Therapy (RT), Cisplatin, Etoposide
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- RTOG Foundation, Inc.
Cachexia, Non-Small-Cell Lung Cancer
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
- Conditions
- Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT04299048
- Testing
- PF-06946860
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference.
- Trial name
- NCT00215930
- Testing
- Vinorelbine, Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer, Postmenopausal Women
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
This research study will test whether dual anti-estrogen therapy (anastrozole and fulvestrant) slows the time to when the cancer progresses.
- Trial name
- NCT00932152
- Testing
- fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pittsburgh
Lung Cancer, Non-Small Cell Lung Cancer
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors.
- Trial name
- NCT00826449
- Testing
- Dasatinib, Erlotinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and…
- Trial name
- NCT02364999
- Testing
- Bevacizumab-Pfizer, Bevacizumab-EU, Paclitaxel
- Where
- 263 sites in United States, Australia and 25 more
- Volunteers
- 719 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
- Trial name
- CheckMate 9LA (NCT03215706)
- Testing
- Ipilimumab, Nivolumab, Carboplatin
- Where
- 116 sites in United States, Argentina and 17 more
- Volunteers
- 719 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
The purpose of this study is to determine whether Eribulin Mesylate Administered in Combination with Pemetrexed is safe and tolerable and to gain a preliminary indication of clinical benefit when administered to Patients with…
- Trial name
- NCT01126736
- Testing
- eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389)
- Where
- 18 sites in United States, Czechia and 3 more
- Volunteers
- 98 people
- Sponsor
- Eisai Inc.
Carcinoma, Non-Small-Cell Lung
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
This trial is divided into Part A and Part B. The primary objective of Part A is to establish the Maximal Tolerated Dose of intermittent high dose afatinib.
- Trial name
- NCT01647711
- Testing
- Dose escalation followed by treatment with MTD
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02197234
- Testing
- Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung…
- Conditions
- Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02621398
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Rutgers, The State University of New Jersey